{"filing":{"accession_number":"0001213900-26-083320","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"ea0299819-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026083320/ea0299819-6k_clearmind.htm"},"events":[{"id":22169,"run_id":20040,"accession_number":"0001213900-26-083320","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces positive safety results from Part A of an FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary drug candidate for Alcohol Use Disorder. All 24 participants completed treatment with no serious adverse events and consistent tolerability across all dose escalations (20 mg to 160 mg). While this is a clinical milestone for a biotech company, it does not fit the discrete event categories (not earnings, M\u0026A, executive changes, impairment, or litigation). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking of its lead asset.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-07-30","form":"6-K","submitted_at":null,"items":[{"id":22035,"accession_number":"0001213900-26-083320","item_number":"EX-99.1","item_title":"ea029981901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive safety results from Part A of an FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary drug candidate for Alcohol Use Disorder. All 24 participants completed treatment with no serious adverse events and consistent tolerability across all dose escalations (20 mg to 160 mg). While this is a clinical milestone for a biotech company, it does not fit the discrete event categories (not earnings, M\u0026A, executive changes, impairment, or litigation). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking of its lead asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:09:08.688533+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22035,"accession_number":"0001213900-26-083320","item_number":"EX-99.1","item_title":"ea029981901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive safety results from Part A of an FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary drug candidate for Alcohol Use Disorder. All 24 participants completed treatment with no serious adverse events and consistent tolerability across all dose escalations (20 mg to 160 mg). While this is a clinical milestone for a biotech company, it does not fit the discrete event categories (not earnings, M\u0026A, executive changes, impairment, or litigation). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking of its lead asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:09:08.688533+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-07-30"}]}